New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:12 EDTHRTXHeron Therapeutics reports Q4 EPS (75c), consensus (53c)
The company said "Net loss was higher in the FY13 quarter primarily due to increased spending related to manufacturing development expenses and higher personnel costs, including stock compensation expense."
News For HRTX From The Last 14 Days
Check below for free stories on HRTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for HRTX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use